US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
CA2194784A1
(en)
*
|
1994-07-13 |
1996-02-01 |
Graham P. Allaway |
Articles of manufacture for removing hiv-1 from a sample, and methods of using same
|
FR2736642B1
(fr)
*
|
1995-07-10 |
1997-09-12 |
Pasteur Institut |
Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
|
EP1516628B1
(de)
|
1995-07-27 |
2013-08-21 |
Genentech, Inc. |
Stabile isotonische lyophilisierte Proteinzusammensetzung
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
EP1500702A1
(de)
|
1996-04-01 |
2005-01-26 |
Genentech, Inc. |
APO-2LI and APO-3 Apoptosis Polypeptides aus der TNFR1 Familie
|
CA2257839C
(en)
|
1996-07-12 |
2012-10-23 |
Genentech, Inc. |
Gamma-heregulin
|
DK0912734T3
(da)
|
1996-07-12 |
2011-02-07 |
Genentech Inc |
Kimæriske heteromultimer-adhæsiner
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US5990281A
(en)
*
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6136958A
(en)
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
US5998598A
(en)
*
|
1997-03-10 |
1999-12-07 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Immunoadhesins and methods of production and use thereof
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
AU739350B2
(en)
|
1997-06-05 |
2001-10-11 |
University Of Texas System, The |
APAF-1, the CED-4 human homolog, an activator of caspase-3
|
DE69837760T3
(de)
|
1997-06-13 |
2012-06-21 |
Genentech, Inc. |
Proteinreinigung mittels chromatographie und darauffolgende filtration auf beladener schicht
|
IL133122A0
(en)
|
1997-06-18 |
2001-03-19 |
Genentech Inc |
Apo-2dcr polypeptides
|
EP1947119A3
(de)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
|
CA2318029C
(en)
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
ATE443723T1
(de)
|
1998-06-12 |
2009-10-15 |
Genentech Inc |
Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
AU3224700A
(en)
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
BRPI0017590B8
(pt)
|
1999-06-25 |
2021-05-25 |
Genentech Inc |
conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
|
KR100850389B1
(ko)
|
1999-06-25 |
2008-08-04 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
ATE438411T1
(de)
|
1999-08-27 |
2009-08-15 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2- antikörpern
|
DE60139864D1
(de)
|
2000-04-28 |
2009-10-22 |
Planet Biotechnology Inc |
Immunoadhesin zur impfung gegen rhinovirus
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
EP1324776B2
(de)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Niederviskose konzentrierte proteinformulierungen
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
EP1427830B1
(de)
|
2001-08-29 |
2012-05-09 |
Genentech, Inc. |
Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
|
NZ573742A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT212
|
US20030228319A1
(en)
|
2002-04-16 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2002362197A1
(en)
|
2001-12-28 |
2003-07-24 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
DK1501856T3
(da)
|
2002-04-10 |
2013-03-25 |
Genentech Inc |
Anti-HER2 antistofvarianter
|
ES2327773T3
(es)
|
2002-05-07 |
2009-11-03 |
Institut Pasteur |
Seleccion de peptidos que unhiben la union de pp1c a proteinas bcl-2, bcl-xl y bcl-w.
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
DK2357006T3
(en)
|
2002-07-31 |
2015-12-21 |
Seattle Genetics Inc |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
CA2496060C
(en)
|
2002-09-11 |
2015-08-04 |
Genentech, Inc. |
Protein purification by ion exchange chromatography
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
HUE026089T2
(hu)
|
2002-12-24 |
2016-05-30 |
Rinat Neuroscience Corp |
NGF elleni antitestek és eljárás alkalmazásukra
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
MXPA05009743A
(es)
|
2003-03-12 |
2006-03-09 |
Genentech Inc |
Composiciones con actividad hematopoyetica e inmune.
|
PL1610820T5
(pl)
|
2003-04-04 |
2014-01-31 |
Genentech Inc |
Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
|
RU2358762C9
(ru)
|
2003-04-09 |
2016-10-10 |
Джинентех, Инк. |
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
|
KR20160114727A
(ko)
|
2003-05-30 |
2016-10-05 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
DK1631313T3
(en)
|
2003-06-05 |
2015-06-15 |
Genentech Inc |
Combination therapy for b cell disorders
|
PT2784084T
(pt)
|
2003-07-08 |
2019-10-01 |
Genentech Inc |
Anticorpos antagonistas contra polipéptidos heterólogos il-17a/f
|
JP4643450B2
(ja)
|
2003-08-08 |
2011-03-02 |
株式会社ペルセウスプロテオミクス |
癌高発現遺伝子
|
CN1938046B
(zh)
|
2003-11-06 |
2014-03-19 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
PL2295073T3
(pl)
|
2003-11-17 |
2014-09-30 |
Genentech Inc |
Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
|
JP4503617B2
(ja)
|
2003-12-23 |
2010-07-14 |
ライナット ニューロサイエンス コーポレイション |
アゴニスト抗trkC抗体および該抗体を用いる方法
|
CN1918178B
(zh)
|
2004-01-12 |
2012-08-22 |
应用分子进化公司 |
Fc区变体
|
ES2337473T3
(es)
|
2004-02-19 |
2010-04-26 |
Genentech, Inc. |
Anticuerpos reparadores con cdr.
|
KR100942849B1
(ko)
|
2004-03-30 |
2010-02-17 |
글락소 그룹 리미티드 |
면역글로불린
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
KR20150092374A
(ko)
|
2004-06-04 |
2015-08-12 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
BRPI0513534A
(pt)
|
2004-07-20 |
2008-05-06 |
Genentech Inc |
inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
|
KR101068289B1
(ko)
|
2004-07-30 |
2011-09-28 |
리나트 뉴로사이언스 코퍼레이션 |
아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008519863A
(ja)
|
2004-11-12 |
2008-06-12 |
シアトル ジェネティクス インコーポレイティッド |
N末端にアミノ安息香酸単位を有するオーリスタチン
|
EP1841793B1
(de)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
KR20170134771A
(ko)
|
2005-01-21 |
2017-12-06 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
PL1853718T3
(pl)
|
2005-02-15 |
2016-01-29 |
Univ Duke |
Przeciwciała anty-CD19 i zastosowania w onkologii
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
EP2551282A3
(de)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antikörper gegen CD38 zur Behandling von multiplem Myelom
|
CA2605507C
(en)
|
2005-04-19 |
2016-06-28 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
EP1885755A4
(de)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
Cd19-antikörper-therapie für autoimmunerkrankungen
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
EP3498289A1
(de)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvalinverbindungen mit phenylalaninseitenkettenmodifikationen am c-terminus
|
DK3248613T3
(da)
|
2005-07-18 |
2022-03-14 |
Seagen Inc |
Beta-glucuronid-lægemiddel-linkerkonjugater
|
BRPI0613770A2
(pt)
|
2005-07-22 |
2009-05-19 |
Y S Therapeutics Co Ltd |
anticorpos anti-cd26 e métodos de uso destes
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
PT2380592T
(pt)
|
2005-11-14 |
2018-06-06 |
Teva Pharmaceuticals Int Gmbh |
Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
EP1954719A2
(de)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Zusammensetzungen und verfahren zur behandlung von krankheiten und leiden in zusammenhang mit zytokin-signalisierung sowie unter verwendung an il-22 und il-22r bindender antikörper
|
WO2007120334A2
(en)
|
2005-12-15 |
2007-10-25 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
US8101365B2
(en)
|
2006-01-05 |
2012-01-24 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
JP2009527227A
(ja)
|
2006-02-17 |
2009-07-30 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
EP2540741A1
(de)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
DK2446904T3
(en)
|
2006-05-30 |
2015-07-27 |
Genentech Inc |
The anti-CD22 antibodies, immunoconjugates and their uses thereof
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
BRPI0712850A8
(pt)
|
2006-06-07 |
2018-05-02 |
Bioalliance Cv |
anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
JP5244103B2
(ja)
|
2006-08-09 |
2013-07-24 |
ホームステッド クリニカル コーポレイション |
器官特異的蛋白質およびその使用方法
|
JP2010501172A
(ja)
|
2006-08-25 |
2010-01-21 |
オンコセラピー・サイエンス株式会社 |
肺癌に対する予後マーカーおよび治療標的
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
MX2009003938A
(es)
|
2006-10-27 |
2009-04-24 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
WO2008061019A2
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
EP2962697A1
(de)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
|
EP2099823B2
(de)
|
2006-12-01 |
2022-02-09 |
Seagen Inc. |
Verschiedene zielmoleküle bindende mittel und ihre verwendung
|
KR101431856B1
(ko)
|
2007-01-22 |
2014-08-27 |
제넨테크, 인크. |
항체의 고분자전해질 침전 및 정제
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン,エルエルシー |
抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
EP2171090B1
(de)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Genexpressionsmarker für tumorresistenz gegen behandlung mit her2-inhibitor
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
ATE543835T1
(de)
|
2007-07-16 |
2012-02-15 |
Genentech Inc |
Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
|
CN104004088B
(zh)
|
2007-09-26 |
2017-11-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
GB0719231D0
(en)
|
2007-10-03 |
2007-11-14 |
Oxford Genome Sciences Uk Ltd |
Protein
|
EP2233149B1
(de)
|
2007-10-16 |
2016-02-10 |
ZymoGenetics, Inc. |
Kombination von Transmembran-Aktivator und Calcium-Modulator und Cyclophilin Ligand Interaktor (TACI) und anti-CD20 Mitteln zur Behandlung von Autoimmunerkrankungen
|
RU2503460C2
(ru)
|
2007-11-07 |
2014-01-10 |
Дженентек Инк. |
Применение противомикробного полипептида для лечения микробных нарушений
|
CN104059143A
(zh)
|
2007-11-12 |
2014-09-24 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
US8563695B2
(en)
|
2007-11-19 |
2013-10-22 |
Genentech, Inc. |
Antibodies that bind β2
|
EP2225275A4
(de)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Proteinformulierung
|
KR20110015409A
(ko)
|
2007-11-29 |
2011-02-15 |
제넨테크, 인크. |
염증성 장 질환에 대한 유전자 발현 마커
|
CA2707483A1
(en)
|
2007-11-30 |
2009-06-11 |
Wolfgang Fraunhofer |
Protein formulations and methods of making same
|
EP2641919A3
(de)
|
2007-11-30 |
2014-05-07 |
Glaxo Group Limited |
Antigenbindende Konstrukte
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
CN106977601A
(zh)
|
2007-12-17 |
2017-07-25 |
辉瑞有限公司 |
间质性膀胱炎的治疗
|
CN105732813A
(zh)
|
2007-12-18 |
2016-07-06 |
生物联合公司 |
识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
DK2602623T3
(en)
|
2008-02-25 |
2015-11-09 |
Nestec Sa |
METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
|
WO2009114560A2
(en)
|
2008-03-10 |
2009-09-17 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
PE20150682A1
(es)
|
2008-10-14 |
2015-05-20 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos
|
WO2010048446A2
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
WO2010056804A1
(en)
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
EP2376120A2
(de)
|
2008-11-25 |
2011-10-19 |
Biogen Idec MA Inc. |
Verwendung von dr6- und p75-antagonisten zur förderung des überlebens von zellen des nervensystems
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
EP3929216A1
(de)
|
2008-12-09 |
2021-12-29 |
F. Hoffmann-La Roche AG |
Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zell-funktion
|
MX2011006516A
(es)
|
2008-12-17 |
2011-08-04 |
Genentech Inc |
Terapia de combinacion de virus de hepatitis c.
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP2401296A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Multivalente und/oder multispezifische rankl-bindende konstrukte
|
CA2753332A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
EP2401298A1
(de)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigenbindende konstrukte
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
TWI507205B
(zh)
|
2009-03-25 |
2015-11-11 |
Genentech Inc |
抗fgfr3抗體及使用方法
|
CA2752908A1
(en)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
NZ595574A
(en)
|
2009-04-01 |
2013-11-29 |
Genentech Inc |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
CN102459340A
(zh)
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
CA2762302A1
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
EP2451843A1
(de)
|
2009-07-07 |
2012-05-16 |
F. Hoffmann-La Roche AG |
Diagnose und behandlung von demyelinisierenden automimmunerkrankungen
|
ES2627909T3
(es)
|
2009-07-15 |
2017-08-01 |
Diatech Holdings, Inc. |
Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
|
CN102639710A
(zh)
|
2009-07-20 |
2012-08-15 |
基因泰克公司 |
克罗恩病的基因表达标记
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
CA2769308A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
BR112012002574A2
(pt)
|
2009-08-06 |
2020-11-03 |
Genentech, Inc. |
método para aprimorar a remoção de vírus na purificação de proteínas
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
HUE036549T2
(hu)
|
2009-10-07 |
2018-07-30 |
Macrogenics Inc |
A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
|
WO2011050069A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
CN102573855A
(zh)
|
2009-10-22 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
US8361744B2
(en)
|
2009-11-05 |
2013-01-29 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
樹状突起棘の密度を促す方法
|
NO2504364T3
(de)
|
2009-11-24 |
2018-01-06 |
|
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP5909449B2
(ja)
|
2009-12-10 |
2016-04-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
重鎖抗体を作製するマウス
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
EP2509626B1
(de)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
|
SG181834A1
(en)
|
2009-12-21 |
2012-07-30 |
Genentech Inc |
Antibody formulation
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
ES2701626T3
(es)
|
2009-12-28 |
2019-02-25 |
Oncotherapy Science Inc |
Anticuerpos anti-CDH3 y sus usos
|
PE20121702A1
(es)
|
2010-01-28 |
2012-12-14 |
Glaxo Group Ltd |
Proteinas de enlace cd127
|
RS59001B1
(sr)
|
2010-02-08 |
2019-08-30 |
Regeneron Pharma |
Miš sa zajedničkim lakim lancem
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
SG183335A1
(en)
|
2010-02-23 |
2012-09-27 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
TWI596114B
(zh)
|
2010-02-24 |
2017-08-21 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
SG183867A1
(en)
|
2010-03-11 |
2012-10-30 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
US8481687B2
(en)
|
2010-04-09 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
PE20130460A1
(es)
|
2010-05-03 |
2013-04-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
KR101915647B1
(ko)
|
2010-05-10 |
2018-11-06 |
아카데미아 시니카 |
항-인플루엔자 활성을 가진 자나미비르 포스포네이트 동족체 및 인플루엔자 바이러스의 오셀타미비르 감수성을 확인하는 방법
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
BR112012029904A2
(pt)
|
2010-05-25 |
2017-08-08 |
Genentech Inc |
métodos de purificação de polipeptídeos
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
CN103119442A
(zh)
|
2010-06-03 |
2013-05-22 |
霍夫曼-拉罗奇有限公司 |
抗体和免疫偶联物的免疫peg成像及其用途
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
WO2012021773A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1beta and il-18, for treatment of disease
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
US20130224191A1
(en)
|
2010-08-27 |
2013-08-29 |
Robert A. Stull |
Notum protein modulators and methods of use
|
CA3201524A1
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AR083546A1
(es)
|
2010-10-25 |
2013-03-06 |
Genentech Inc |
Tratamiento de inflamacion gastrointestinal, soriasis y asma
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
NZ609567A
(en)
|
2010-11-05 |
2015-05-29 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
MX356400B
(es)
|
2010-12-08 |
2018-05-28 |
Abbvie Stemcentrx Llc |
Moduladores novedosos y metodos de uso.
|
KR20140002711A
(ko)
|
2010-12-23 |
2014-01-08 |
네스텍 소시에테아노님 |
항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CN103687619A
(zh)
|
2011-02-14 |
2014-03-26 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
CA2829968A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
JP6248029B2
(ja)
|
2011-03-31 |
2017-12-13 |
ジェネンテック, インコーポレイテッド |
ベータ7インテグリンアンタゴニストの投与方法
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
PT2726094T
(pt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Alvo terapêutico e de diagnóstico
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
SG10201606158TA
(en)
|
2011-08-05 |
2016-09-29 |
Regeneron Pharma |
Humanized universal light chain mice
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2751562B1
(de)
|
2011-09-02 |
2015-09-16 |
Nestec S.A. |
Profilierung von signalwegproteinen zur bestimmung der therapeutischen wirksamkeit
|
WO2013067301A1
(en)
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス,インコーポレイテッド |
Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
EP2776470A2
(de)
|
2011-11-11 |
2014-09-17 |
Rinat Neuroscience Corporation |
Für trop-2 spezifische antikörper und ihre verwendungen
|
IN2014CN04652A
(de)
|
2011-12-22 |
2015-09-18 |
Rinat Neuroscience Corp |
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
TWI530505B
(zh)
*
|
2011-12-27 |
2016-04-21 |
財團法人生物技術開發中心 |
輕鏈橋接型雙特異性抗體
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
HUE037021T2
(hu)
|
2012-02-24 |
2018-08-28 |
Abbvie Stemcentrx Llc |
DLL3- modulátorok és eljárások alkalmazásukra
|
MY171729A
(en)
|
2012-03-27 |
2019-10-25 |
Genentech Inc |
Improved harvest operations for recombinant proteins
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
EP2847230B1
(de)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimerkonstrukte aus schweren immunoglobulinketten mit mutationen in der fc-domäne
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
JP6211084B2
(ja)
|
2012-08-21 |
2017-10-11 |
アカデミア シニカAcademia Sinica |
ベンゾシクロオクチン化合物およびその使用
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CN104870056A
(zh)
|
2012-10-05 |
2015-08-26 |
弗·哈夫曼-拉罗切有限公司 |
用于诊断和治疗炎性肠病的方法
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
MX2015005874A
(es)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
|
RU2015122726A
(ru)
|
2012-11-15 |
2017-01-10 |
Дженентек, Инк. |
ОПОСРЕДОВАННАЯ ИОННОЙ СИЛОЙ рН-ГРАДИЕНТНАЯ ИОНООБМЕННАЯ ХРОМАТОГРАФИЯ
|
MX2015006758A
(es)
|
2012-11-28 |
2016-06-10 |
Zymeworks Inc |
Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
US10047163B2
(en)
|
2013-02-08 |
2018-08-14 |
Abbvie Stemcentrx Llc |
Multispecific constructs
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AU2014218730B2
(en)
|
2013-02-22 |
2018-12-13 |
Abbvie Stemcentrx Llc |
Novel antibody conjugates and uses thereof
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
DK2968466T3
(en)
|
2013-03-13 |
2018-10-22 |
Hoffmann La Roche |
Reduced oxidation formulations
|
WO2014160497A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Formulations with reduced oxidation
|
MY185551A
(en)
|
2013-03-13 |
2021-05-19 |
Genentech Inc |
Antibody formulations
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
CA2906784C
(en)
|
2013-03-15 |
2023-02-28 |
The Centre For Drug Research And Development |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
US9441035B2
(en)
|
2013-03-15 |
2016-09-13 |
Genentech, Inc. |
Cell culture media and methods of antibody production
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
EP2970875B1
(de)
|
2013-03-15 |
2020-04-15 |
F.Hoffmann-La Roche Ag |
Zellkulturzusammensetzungen mit antioxidanzien und verfahren zur herstellung von polypeptiden
|
SG11201507974RA
(en)
|
2013-03-27 |
2015-10-29 |
Genentech Inc |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
JP2016520058A
(ja)
|
2013-05-07 |
2016-07-11 |
ライナット ニューロサイエンス コーポレイション |
抗グルカゴン受容体抗体およびその使用方法
|
CN105392780A
(zh)
|
2013-05-24 |
2016-03-09 |
雀巢产品技术援助有限公司 |
用于预测肠易激综合征诊断的途径特异性测定
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
EP4252769A3
(de)
|
2013-07-09 |
2023-11-29 |
Annexon, Inc. |
Anti-komplementfaktor-c1q-antikörper und verwendungen davon
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
WO2015010100A2
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
WO2015015401A2
(en)
|
2013-08-02 |
2015-02-05 |
Pfizer Inc. |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
BR112016004245A2
(pt)
|
2013-08-28 |
2017-10-17 |
Stemcentrx Inc |
moduladores de sez6 e métodos de uso
|
US20150093800A1
(en)
|
2013-09-05 |
2015-04-02 |
Genentech, Inc. |
Method for chromatography reuse
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
AU2014324703C1
(en)
|
2013-09-27 |
2020-10-29 |
Genentech, Inc. |
Anti-PDL1 antibody formulations
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
WO2015069459A1
(en)
|
2013-11-05 |
2015-05-14 |
Novartis Ag |
Organic compounds
|
EP3094973B1
(de)
|
2013-11-07 |
2020-07-29 |
Diagnodus Limited |
Biomarker
|
WO2015073580A1
(en)
|
2013-11-13 |
2015-05-21 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
CA2931356A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
JP2017501157A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及び抗cd20抗体を使用してがんを治療する方法
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2015095953A1
(en)
|
2013-12-27 |
2015-07-02 |
The Centre For Drug Research And Development |
Sulfonamide-containing linkage systems for drug conjugates
|
CN106459920B
(zh)
|
2014-01-16 |
2020-10-30 |
中央研究院 |
治疗及检测癌症的组合物及方法
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
HRP20211748T1
(hr)
|
2014-03-14 |
2022-02-18 |
F. Hoffmann - La Roche Ag |
Postupci i sastavi za sekreciju heterolognih polipeptida
|
RS65360B1
(sr)
|
2014-03-21 |
2024-04-30 |
Teva Pharmaceuticals Int Gmbh |
Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
|
KR20210088756A
(ko)
|
2014-03-21 |
2021-07-14 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
MX2016012282A
(es)
|
2014-03-27 |
2017-01-06 |
Genentech Inc |
Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
US20150344585A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
KR102576850B1
(ko)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-her2 글리코항체 및 이의 용도
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
AU2015265457B2
(en)
|
2014-05-28 |
2021-02-18 |
Zymeworks Bc Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
US20170240631A1
(en)
|
2014-08-08 |
2017-08-24 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
KR102494557B1
(ko)
|
2014-09-17 |
2023-02-02 |
자임워크스 비씨 인코포레이티드 |
세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
EP3215526A1
(de)
|
2014-11-05 |
2017-09-13 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von zweikettigen proteinen in bakterien
|
CN107207587B
(zh)
|
2014-11-05 |
2022-04-19 |
安尼艾克松股份有限公司 |
人源化抗-补体因子c1q抗体及其应用
|
MX2017005925A
(es)
|
2014-11-05 |
2017-11-08 |
Genentech Inc |
Metodos de producción de proteínas de cadena doble en bacterias.
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
AU2015348940A1
(en)
|
2014-11-19 |
2017-05-25 |
Société des Produits Nestlé S.A. |
Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
|
WO2016087514A1
(en)
|
2014-12-02 |
2016-06-09 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
GB201421901D0
(en)
|
2014-12-09 |
2015-01-21 |
Cambridge Entpr Ltd |
A method of rational antibody design
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TWI736523B
(zh)
|
2015-01-24 |
2021-08-21 |
中央研究院 |
新穎聚醣結合物及其使用方法
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
JP6942633B2
(ja)
|
2015-01-30 |
2021-09-29 |
アカデミア シニカAcademia Sinica |
抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AR103782A1
(es)
|
2015-02-26 |
2017-05-31 |
Genentech Inc |
ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
|
ES2761726T3
(es)
|
2015-03-06 |
2020-05-20 |
Hoffmann La Roche |
DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
|
AU2016232715A1
(en)
|
2015-03-19 |
2017-09-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
DK3280441T3
(da)
|
2015-04-07 |
2021-11-15 |
Alector Llc |
Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
|
KR102405099B1
(ko)
|
2015-04-13 |
2022-06-07 |
화이자 인코포레이티드 |
치료 항체 및 그의 용도
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
CA2984638A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
EP3307779A2
(de)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33-antikörper und verfahren zur verwendung davon
|
CN107922480B
(zh)
|
2015-06-12 |
2022-09-23 |
艾利妥 |
抗cd33抗体及其使用方法
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EP3341411A1
(de)
|
2015-08-28 |
2018-07-04 |
Alector LLC |
Anti-siglec-7-antikörper und verfahren zur verwendung davon
|
US10935544B2
(en)
|
2015-09-04 |
2021-03-02 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
US20190330335A1
(en)
|
2015-10-06 |
2019-10-31 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
KR20180075537A
(ko)
|
2015-10-06 |
2018-07-04 |
제넨테크, 인크. |
다발성 경화증을 치료하기 위한 방법
|
CN108283001B
(zh)
|
2015-10-08 |
2022-08-19 |
酵活有限公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
CN115636880A
(zh)
|
2015-10-23 |
2023-01-24 |
辉瑞有限公司 |
抗il-2抗体及其组合物和用途
|
WO2017075432A2
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
EP3165237B1
(de)
|
2015-11-03 |
2018-12-19 |
Industrial Technology Research Institute |
Antikörperwirkstoffkonjugat und herstellungsverfahren dafür
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
BR112018010945A2
(pt)
|
2015-12-30 |
2018-12-04 |
Genentech Inc |
formulações com degradação de polissorbato reduzida
|
WO2017117304A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
WO2017122098A2
(en)
|
2016-01-10 |
2017-07-20 |
Neotx Therapeutics Ltd. |
Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy.
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
JP7073266B2
(ja)
|
2016-03-25 |
2022-05-23 |
シージェン インコーポレイテッド |
Peg化薬物リンカー及びその中間体を調製するためのプロセス
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
JP2019513144A
(ja)
|
2016-03-29 |
2019-05-23 |
オービーアイ ファーマ,インコーポレイテッド |
抗体、医薬組成物及び方法
|
CA3019373A1
(en)
|
2016-03-29 |
2017-10-05 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
KR20180128496A
(ko)
|
2016-04-22 |
2018-12-03 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
|
CN114703244A
(zh)
|
2016-05-10 |
2022-07-05 |
豪夫迈·罗氏有限公司 |
重组产生多肽期间减少三硫键的方法
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
KR20190039929A
(ko)
|
2016-06-17 |
2019-04-16 |
제넨테크, 인크. |
다중 특이적 항체의 정제
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
TWI752988B
(zh)
|
2016-07-27 |
2022-01-21 |
台灣浩鼎生技股份有限公司 |
免疫性/治療性聚醣組合物及其用途
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
AU2017312540B2
(en)
|
2016-08-15 |
2023-02-02 |
Genentech, Inc. |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
MX2019003338A
(es)
|
2016-09-23 |
2019-09-26 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento de cefalea en racimos.
|
WO2018055574A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
BR112019010356A2
(pt)
|
2016-11-21 |
2019-08-27 |
Obi Pharma Inc |
molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
KR102646046B1
(ko)
|
2017-01-06 |
2024-03-08 |
바이오션, 인코포레이티드 |
Erbb2 항체 및 이의 용도
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018158658A1
(en)
|
2017-03-03 |
2018-09-07 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
IL269398B2
(en)
|
2017-03-24 |
2024-05-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
WO2018220584A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
AU2018311055A1
(en)
|
2017-08-03 |
2019-11-14 |
Alector Llc |
Anti-TREM2 antibodies and methods of use thereof
|
CN117700548A
(zh)
|
2017-08-03 |
2024-03-15 |
艾利妥 |
抗cd33抗体及其使用方法
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
CN111954541A
(zh)
|
2018-01-25 |
2020-11-17 |
Acm生物实验室私人有限公司 |
包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
|
US11396551B2
(en)
|
2018-02-01 |
2022-07-26 |
Pfizer Inc. |
Chimeric antigen receptors targeting CD70
|
US11377500B2
(en)
|
2018-02-01 |
2022-07-05 |
Pfizer Inc. |
Antibodies specific for CD70 and their uses
|
US11485782B2
(en)
|
2018-03-14 |
2022-11-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
AU2019240111A1
(en)
|
2018-03-21 |
2020-09-17 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
EP3797121B1
(de)
|
2018-05-23 |
2024-06-19 |
Pfizer Inc. |
Antikörper spezifisch für cd3 und deren verwendung
|
EA202092595A1
(ru)
|
2018-06-08 |
2021-04-12 |
Алектор Ллс |
Антитела к siglec-7 и способы их применения
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
IL270214B1
(en)
|
2018-07-13 |
2024-03-01 |
Alector Llc |
Anti-sortilin antibodies and methods of using them
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
EA202190183A1
(ru)
|
2018-07-27 |
2021-05-18 |
Алектор Ллс |
Антитела к siglec-5 и способы их применения
|
WO2020033485A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
EA202190235A1
(ru)
|
2018-08-31 |
2021-07-02 |
Алектор Ллс |
Антитела к cd33 и способы их применения
|
CN112996539A
(zh)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
TWI824043B
(zh)
|
2018-10-25 |
2023-12-01 |
西班牙商瑪製藥股份有限公司 |
藥物抗體共軛物
|
CA3117051A1
(en)
|
2018-11-05 |
2020-05-14 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
EP3953380A4
(de)
|
2019-04-12 |
2023-01-25 |
Geltor, Inc. |
Rekombinantes elastin und herstellung davon
|
JP2022528804A
(ja)
|
2019-04-18 |
2022-06-15 |
ジェネンテック, インコーポレイテッド |
抗体力価試験
|
BR112021019571A2
(pt)
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
KR20220006519A
(ko)
|
2019-05-10 |
2022-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
항체 약물 접합체
|
JP2022531978A
(ja)
|
2019-05-15 |
2022-07-12 |
ネオティーエックス セラピューティクス リミテッド |
癌治療
|
WO2020232262A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
Assay detection methods for vcam-1 and calprotectin
|
WO2020232295A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
EP3973290A1
(de)
|
2019-05-23 |
2022-03-30 |
ProciseDx Inc. |
Testverfahren zum nachweis von humanem serumalbumin, vitamin d, c-reaktivem protein und anti-transglutaminase-antikörper
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
WO2020247159A1
(en)
|
2019-06-06 |
2020-12-10 |
Procisedx Inc. |
DETECTION OF HEMOGLOBIN A1C (HbA1c) IN BLOOD
|
EP3990922A1
(de)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Nachweis von anti-tnf-alpha biologika und anti-wirkstoff-antikörpern
|
US11865177B2
(en)
|
2019-06-28 |
2024-01-09 |
Genentech, Inc. |
Composition and methods for stabilizing liquid protein formulations
|
EP3998083A4
(de)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörper gegen mutationstyp fgfr3 und verwendung davon
|
CA3147103A1
(en)
|
2019-07-19 |
2021-01-28 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and methods of use thereof
|
KR20220038415A
(ko)
|
2019-07-26 |
2022-03-28 |
벤더르빌트 유니버시티 |
엔테로바이러스 d68에 대한 인간 모노클로날 항체
|
EP4025253B1
(de)
|
2019-09-05 |
2024-03-20 |
Pharma Mar, S.A. |
Arzneimittel-antikörper-konjugate
|
BR112022011337A2
(pt)
|
2019-12-12 |
2022-08-23 |
Alector Llc |
Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
IL295310A
(en)
|
2020-02-11 |
2022-10-01 |
Univ Vanderbilt |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
US20230090014A1
(en)
|
2020-02-28 |
2023-03-23 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
Anti-cd47/anti-pd-l1 antibody and applications thereof
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
SI4045533T1
(sl)
|
2020-03-26 |
2024-03-29 |
Vanderbilt University |
Človeška monoklonska protitelesa proti koronavirusu s hudim akutnim respiratornim sindromom 2 (SARS-COV-2)
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
TW202203980A
(zh)
|
2020-04-21 |
2022-02-01 |
西班牙商瑪製藥股份有限公司 |
藥物抗體共軛物
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
WO2021226290A1
(en)
|
2020-05-05 |
2021-11-11 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
WO2021247618A1
(en)
|
2020-06-02 |
2021-12-09 |
10X Genomics, Inc. |
Enrichment of nucleic acid sequences
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
EP4182346A1
(de)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutische antikörper und deren verwendungen
|
TW202214705A
(zh)
|
2020-09-22 |
2022-04-16 |
大陸商南京聖和藥業股份有限公司 |
抗tigit抗體及雙抗體和它們的應用
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
IL302390A
(en)
|
2020-11-09 |
2023-06-01 |
Takeda Pharmaceuticals Co |
Drug antibody conjugates
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
TW202244060A
(zh)
|
2021-01-20 |
2022-11-16 |
美商昂科里斯龐司公司 |
免疫調節抗體及其用途
|
CN117440798A
(zh)
|
2021-04-12 |
2024-01-23 |
Acm 生物实验室私人有限公司 |
包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途
|
EP4334343A2
(de)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
|
WO2022256313A1
(en)
|
2021-06-01 |
2022-12-08 |
10X Genomics, Inc. |
Validation of a unique molecular identifier associated with a nucleic acid sequence of interest
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
AU2022387613A1
(en)
|
2021-11-10 |
2024-05-30 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023166418A2
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|